SAB Biotherapeutics Warrant
SABSW
11 hedge funds and large institutions have $52.1K invested in SAB Biotherapeutics Warrant in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
19% more capital invested
Capital invested by funds: $43.8K → $52.1K (+$8.29K)
9.68% more ownership
Funds ownership: 2.23% → 11.91% (+9.7%)
8% less funds holding
Funds holding: 12 → 11 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$4 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$1.62K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$482 |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$276 |
| 4 |
Morgan Stanley
New York
|
-$93 |
| 5 |
CS
Clear Street
New York
|
-$4 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LP
1
LMR Partners
London,
United Kingdom
| $25.6K | – | – | – |
|
|
SCM
2
Shaolin Capital Management
Miami,
Florida
| $11.8K | -$1.62K | -43,822 | -15% |
|
|
3
Morgan Stanley
New York
| $6.94K | -$93 | -2,500 | -2% |
|
|
YCM
4
Yakira Capital Management
Westport,
Connecticut
| $5.14K | – | – | – |
|
5
Walleye Capital
New York
| $1.1K | – | – | – |
|
6
Walleye Trading
New York
| $735 | – | – | – |
|
|
WAM
7
Wolverine Asset Management
Chicago,
Illinois
| $726 | -$276 | -7,464 | -33% |
|
|
NA
8
NewEdge Advisors
New Orleans,
Louisiana
| $50 | – | – | – |
|
|
9
Bank of America
Charlotte,
North Carolina
| $9 | +$4 | +100 | +100% |
|
|
10
UBS Group
Zurich,
Switzerland
| $3 | +$2 | +56 | New |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $2 | – | – | – |
|
|
12
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$482 | -12,366 | Closed |
|
|
CS
13
Clear Street
New York
| – | -$4 | -100 | Closed |
|
SABSW Hedge Fund Activity: Q2 2024 in Review
11 of the 6,927 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q2 2024, worth a combined $52.1K — up 19% from $43.8K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SABSW and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 1 added.
The largest buyer was Bank of America, adding an estimated $4. The largest seller was Shaolin Capital Management, cutting an estimated $1.62K.
- 11 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q2 2024, down from 12 in Q1 2024.
- Funds reported $52.1K of SAB Biotherapeutics Warrant stock for Q2 2024, up 19% quarter-over-quarter.
- 1 fund opened new SAB Biotherapeutics Warrant positions in Q2 2024 and 2 closed out, a net change of -1 holder.
- The largest SAB Biotherapeutics Warrant buyer in Q2 2024 was Bank of America, an estimated $4 added.
- The largest SAB Biotherapeutics Warrant seller in Q2 2024 was Shaolin Capital Management, an estimated $1.62K sold.
Based on aggregated 13F filings for Q2 2024.